Skip to main
  1. Stocks
  2. Jazz Pharmaceuticals
  3. Forecast
JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals (JAZZ) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 44%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Jazz Pharmaceuticals is supported by a diversified portfolio of nine approved drugs across neuroscience and oncology, with Xywav, Xyrem, Epidiolex, Zepzelca, Rylaze, and Vyxeos providing substantial recurring cash flow and helping offset competitive pressure in the sleep franchise. The company’s outlook is further strengthened by Ziihera’s early launch in gastroesophageal adenocarcinoma, where sales reached $21M in 3Q26 and management sees broader HER2+ expansion potential, alongside steady Epidiolex growth and controlled expenses. Pipeline optionality also matters, with ABS-1230, JZP269, and other oncology and rare-disease programs creating multiple catalysts that could support revenue growth and EBITDA expansion over time.

Bears say

Jazz Pharmaceuticals is viewed negatively because its core narcolepsy franchise is expected to face mounting erosion from generic entrants, Lumryz expansion, and orexin competition, even as 2027 patient growth supports only a flat franchise at about $2.06B. The outlook is further weakened by pipeline and regulatory risk, reimbursement risk, and the possibility that slower-than-expected uptake of commercial products and failed additional indications could limit growth. Oncology adds upside, but it remains a highly competitive and high-risk area, while broader macro headwinds such as tariffs and MFN could pressure both top- and bottom-line performance.

Jazz Pharmaceuticals (JAZZ) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 44% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Jazz Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Jazz Pharmaceuticals (JAZZ) Analyst Forecast & Price Prediction

Get the latest Jazz Pharmaceuticals (JAZZ) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Jazz Pharmaceuticals (JAZZ)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Jazz Pharmaceuticals (JAZZ) Forecast

Analysts have given Jazz Pharmaceuticals (JAZZ) a Buy based on their latest research and market trends.

According to 18 analysts, Jazz Pharmaceuticals (JAZZ) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $298.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $298.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Jazz Pharmaceuticals (JAZZ)


Jazz Pharmaceuticals (JAZZ) Analyst Forecast & Price Prediction

Get the latest Jazz Pharmaceuticals (JAZZ) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Jazz Pharmaceuticals (JAZZ)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover JAZZ stock data and trends